- Home
- NUVB vs OPK Comparison
NUVB vs OPK Comparison
Compare NUVB & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVB
- OPK
- Stock Information
- Founded
- NUVB 2018
- OPK 2007
- Country
- NUVB United States
- OPK United States
- Employees
- NUVB N/A
- OPK N/A
- Industry
- NUVB Biotechnology: Pharmaceutical Preparations
- OPK Biotechnology: Pharmaceutical Preparations
- Sector
- NUVB Health Care
- OPK Health Care
- Exchange
- NUVB Nasdaq
- OPK Nasdaq
- Market Cap
- NUVB 1.1B
- OPK 1.0B
- IPO Year
- NUVB N/A
- OPK 1995
- Fundamental
- Price
- NUVB $3.28
- OPK $1.39
- Analyst Decision
- NUVB Strong Buy
- OPK Buy
- Analyst Count
- NUVB 6
- OPK 4
- Target Price
- NUVB $8.17
- OPK $2.75
- AVG Volume (30 Days)
- NUVB 6.7M
- OPK 2.0M
- Earning Date
- NUVB 11-05-2025
- OPK 11-06-2025
- Dividend Yield
- NUVB N/A
- OPK N/A
- EPS Growth
- NUVB N/A
- OPK N/A
- EPS
- NUVB N/A
- OPK N/A
- Revenue
- NUVB $14,355,000.00
- OPK $664,029,000.00
- Revenue This Year
- NUVB $332.80
- OPK N/A
- Revenue Next Year
- NUVB $360.12
- OPK $0.84
- P/E Ratio
- NUVB N/A
- OPK N/A
- Revenue Growth
- NUVB 900.35
- OPK N/A
- 52 Week Low
- NUVB $1.54
- OPK $1.11
- 52 Week High
- NUVB $4.09
- OPK $2.04
- Technical
- Relative Strength Index (RSI)
- NUVB 58.18
- OPK 51.88
- Support Level
- NUVB $3.20
- OPK $1.34
- Resistance Level
- NUVB $3.41
- OPK $1.44
- Average True Range (ATR)
- NUVB 0.27
- OPK 0.04
- MACD
- NUVB -0.03
- OPK -0.00
- Stochastic Oscillator
- NUVB 33.55
- OPK 50.00
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
About OPK OPKO Health Inc.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.